IDEXX Laboratories, Inc. (IDXX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
↓
32.06
↓-18% vs avg
5yr avg: 39.21
30Y Low9.2·High55.8
P/FCF
↓
43.78
↓-34% vs avg
5yr avg: 66.49
30Y Low13.1·High89.6
P/B Ratio
↓
29.11
↓-36% vs avg
5yr avg: 45.26
30Y Low2.0·High128.6
ROE
↓
66.2%
↑-22% vs avg
5yr avg: 84.4%
30Y Low-7%·High144%
Debt/EBITDA
↓
0.73
↓-24% vs avg
5yr avg: 0.97
30Y Low0.0·High3.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IDXX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
IDEXX Laboratories, Inc. trades at 44.3x earnings, 19% below its 5-year average of 54.6x, sitting at the 71st percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 100%. On a free-cash-flow basis, the stock trades at 43.8x P/FCF, 34% below the 5-year average of 66.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $46.1B | $54.6B | $34.4B | $46.6B | $34.5B | $57.0B | $43.3B | $22.9B | $16.5B | $14.0B | $10.7B |
| Enterprise Value | $47.0B | $55.5B | $35.1B | $47.2B | $35.9B | $57.9B | $44.0B | $23.8B | $17.3B | $15.1B | $11.7B |
| P/E Ratio → | 44.28 | 51.72 | 38.75 | 55.17 | 50.80 | 76.57 | 74.50 | 53.40 | 43.67 | 53.19 | 48.06 |
| P/S Ratio | 10.72 | 12.68 | 8.83 | 12.73 | 10.25 | 17.73 | 16.02 | 9.50 | 7.44 | 7.11 | 6.00 |
| P/B Ratio | 29.11 | 34.00 | 21.57 | 31.40 | 56.70 | 82.62 | 68.51 | 128.55 | — | — | — |
| P/FCF | 43.78 | 51.81 | 43.13 | 60.31 | 87.57 | 89.63 | 80.21 | 75.21 | 59.38 | 47.23 | 39.51 |
| P/OCF | 39.15 | 46.33 | 37.05 | 51.42 | 63.56 | 75.45 | 66.89 | 49.79 | 41.13 | 37.52 | 31.86 |
P/E links to full P/E history page with 30-year chart
IDXX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
IDEXX Laboratories, Inc.'s enterprise value stands at 32.1x EBITDA, 18% below its 5-year average of 39.2x. The Healthcare sector median is 14.1x, placing the stock at a 127% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.89 | 9.01 | 12.90 | 10.65 | 18.00 | 16.24 | 9.90 | 7.83 | 7.66 | 6.59 |
| EV / EBITDA | 32.06 | 37.83 | 27.91 | 38.96 | 35.49 | 55.85 | 55.62 | 37.20 | 30.17 | 30.39 | 27.32 |
| EV / EBIT | 34.57 | 40.72 | 30.78 | 42.82 | 39.86 | 62.08 | 63.25 | 43.09 | 35.20 | 36.05 | 33.08 |
| EV / FCF | — | 52.66 | 44.00 | 61.10 | 91.01 | 91.02 | 81.36 | 78.44 | 62.54 | 50.85 | 43.39 |
IDXX Profitability
Margins and return-on-capital ratios measuring operating efficiency
IDEXX Laboratories, Inc. earns an operating margin of 31.6%. Operating margins have expanded from 30.0% to 31.6% over the past 3 years, signaling improving operational efficiency. Return on equity of 66.2% is exceptionally high. ROIC of 42.5% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% |
| Operating Margin | 31.6% | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% |
| Net Profit Margin | 24.6% | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.2% | 66.2% | 57.7% | 80.7% | 104.6% | 112.6% | 143.5% | 507.4% | — | — | — |
| ROA | 31.9% | 31.9% | 27.1% | 28.1% | 26.2% | 31.5% | 28.2% | 25.4% | 23.2% | 16.2% | 14.8% |
| ROIC | 42.5% | 42.5% | 38.5% | 40.5% | 38.1% | 49.4% | 43.2% | 40.9% | 39.1% | 31.6% | 27.7% |
| ROCE | 61.4% | 61.4% | 49.8% | 57.5% | 56.4% | 55.1% | 49.3% | 59.0% | 66.6% | 63.3% | 57.7% |
IDXX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
IDEXX Laboratories, Inc. carries a Debt/EBITDA ratio of 0.7x, which is very conservative (77% below the sector average of 3.3x). Net debt stands at $897M ($1.1B total debt minus $180M cash). Interest coverage of 35.6x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.67 | 0.67 | 0.62 | 0.72 | 2.41 | 1.49 | 1.59 | 6.02 | — | — | — |
| Debt / EBITDA | 0.73 | 0.73 | 0.78 | 0.88 | 1.45 | 0.99 | 1.27 | 1.67 | 1.74 | 2.54 | 2.81 |
| Net Debt / Equity | — | 0.56 | 0.44 | 0.41 | 2.23 | 1.28 | 0.98 | 5.51 | — | — | — |
| Net Debt / EBITDA | 0.61 | 0.61 | 0.56 | 0.51 | 1.34 | 0.86 | 0.78 | 1.53 | 1.53 | 2.16 | 2.45 |
| Debt / FCF | — | 0.85 | 0.88 | 0.79 | 3.44 | 1.39 | 1.15 | 3.22 | 3.16 | 3.62 | 3.89 |
| Interest Coverage | 35.61 | 35.61 | 36.57 | 26.52 | 22.58 | 31.28 | 20.98 | 17.82 | 14.17 | 11.24 | 11.04 |
IDXX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.17x means IDEXX Laboratories, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.84x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.57x to 1.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.17 | 1.17 | 1.31 | 1.57 | 0.89 | 1.25 | 1.82 | 0.94 | 0.85 | 0.97 | 0.90 |
| Quick Ratio | 0.84 | 0.84 | 0.95 | 1.17 | 0.59 | 0.90 | 1.46 | 0.67 | 0.62 | 0.80 | 0.74 |
| Cash Ratio | 0.16 | 0.16 | 0.27 | 0.48 | 0.09 | 0.19 | 0.66 | 0.12 | 0.16 | 0.47 | 0.42 |
| Asset Turnover | — | 1.28 | 1.18 | 1.12 | 1.23 | 1.32 | 1.18 | 1.31 | 1.44 | 1.15 | 1.16 |
| Inventory Turnover | 4.35 | 4.35 | 3.98 | 3.87 | 3.71 | 4.93 | 5.41 | 5.34 | 5.61 | 5.30 | 5.06 |
| Days Sales Outstanding | — | 58.79 | 52.57 | 52.79 | 53.21 | 48.31 | 50.53 | 46.63 | 42.63 | 50.06 | 47.73 |
IDXX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
IDEXX Laboratories, Inc. returns 2.6% to shareholders annually primarily through share buybacks. The earnings yield of 2.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.3% | 1.9% | 2.6% | 1.8% | 2.0% | 1.3% | 1.3% | 1.9% | 2.3% | 1.9% | 2.1% |
| FCF Yield | 2.3% | 1.9% | 2.3% | 1.7% | 1.1% | 1.1% | 1.2% | 1.3% | 1.7% | 2.1% | 2.5% |
| Buyback Yield | 2.6% | 2.2% | 2.4% | 0.2% | 2.4% | 1.3% | 0.4% | 1.3% | 2.2% | 2.1% | 2.9% |
| Total Shareholder Yield | 2.6% | 2.2% | 2.4% | 0.2% | 2.4% | 1.3% | 0.4% | 1.3% | 2.2% | 2.1% | 2.9% |
| Shares Outstanding | — | $81M | $83M | $84M | $85M | $87M | $87M | $88M | $88M | $90M | $91M |
Peer Comparison
Compare IDXX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IDXXYou | $46B | 44.3 | 32.1 | 43.8 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 ZTS | $47B | 18.5 | 13.3 | 20.6 | 70.5% | 38.0% | 66.0% | 26.9% | 2.3 |
 HSIC | $8B | 22.2 | 11.1 | 14.5 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 ELAN | $13B | -55.7 | 17.7 | 46.0 | 43.5% | 5.3% | -3.7% | 1.9% | 4.3 |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 NEOG | $2B | -1.8 | 20.6 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 CHWY | $10B | 27.0 | 44.5 | 22.5 | 29.2% | 0.9% | 101.8% | 28.0% | 2.2 |
 DHR | $124B | 34.7 | 18.1 | 23.5 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.3 | 16.8 | 18.7 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 A | $33B | 25.8 | 19.7 | 28.9 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full IDXX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See IDXX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDXX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IDXX vs ZTS
Side-by-side business, growth, and profitability comparison vs Zoetis Inc..
Start ComparisonIDXX — Frequently Asked Questions
Quick answers to the most common questions about buying IDXX stock.
What is IDEXX Laboratories, Inc.'s P/E ratio?
IDEXX Laboratories, Inc.'s current P/E ratio is 44.3x. The historical average is 37.6x. This places it at the 71th percentile of its historical range.
What is IDEXX Laboratories, Inc.'s EV/EBITDA?
IDEXX Laboratories, Inc.'s current EV/EBITDA is 32.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.2x.
What is IDEXX Laboratories, Inc.'s ROE?
IDEXX Laboratories, Inc.'s return on equity (ROE) is 66.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 37.8%.
Is IDXX stock overvalued?
Based on historical data, IDEXX Laboratories, Inc. is trading at a P/E of 44.3x. This is at the 71th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are IDEXX Laboratories, Inc.'s profit margins?
IDEXX Laboratories, Inc. has 61.8% gross margin and 31.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does IDEXX Laboratories, Inc. have?
IDEXX Laboratories, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.